

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 April 2001 (12.04.2001)

PCT

(10) International Publication Number
WO 01/24773 A1

(51) International Patent Classification⁷: **A61K 9/127**,
48/00, C12N 15/88

(21) International Application Number: **PCT/GB00/03773**

(22) International Filing Date: **2 October 2000 (02.10.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
99307786.6 **1 October 1999 (01.10.1999)** **EP**

(71) Applicant (for all designated States except US):
LIPOXEN LIMITED [GB/GB]; 1 Portland Place,
London W1N 3AA (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GREGORIADIS**,
Gregory [CA/GB]; Lipoxen Limited, 2d Wimpole Street,
London W1N 7AA (GB). **PERRIE**, **Yvonne** [GB/GB];
School of Life and Health Sciences, Aston University, As-
ton Triangle, Birmingham B4 7ET (GB).

(74) Agent: **GILL JENNINGS & EVERY**; Broadgate House,
7 Eldon Street, London EC2M 7LH (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **LIPOSOME-ENTRAPPED DNA ORAL VACCINES**

(57) Abstract: An oral vaccine comprises liposomes and complexed or, preferably, entrapped DNA operatively encoding an antigen, in which the liposomes are formed from components including cationic compounds and zwitterionic phospholipids. The hydrophobic groups within the liposome forming compounds must include at least one group which is saturated. This is believed to raise the transition temperature, rendering the liposomes more stable when delivered orally. The compositions have been found to give detectable increased in IgA levels, secreted immunoglobulins of importance in efficacious oral vaccine delivery.

WO 01/24773 A1